Enhanced AAV-mediated gene transfer for retinal therapies

Patent metadata

Field	Value
Publication number	US-10266845-B2
Application number	US-201615246001-A
Country	US
Kind code	B2
Filing date	Aug 24, 2016
Priority date	Feb 8, 2013
Publication date	Apr 23, 2019
Grant date	Apr 23, 2019

Abstract

Described herein are capsid proteins and adeno-associated viruses capable of targeting various types of ocular cells including bipolar and horizontal cells. Also described herein are methods of treating various ocular disorders in a subject in need thereof by administering to the subject an effective concentration of a composition comprising the recombinant adeno-associated virus (AAV) of the invention.

First claim

What is claimed is:

1. A method of preventing, arresting progression of, or ameliorating vision loss associated with an ocular disorder in a subject, said method comprising administering to said subject an effective concentration of a composition comprising a recombinant adeno-associated virus (AAV) having a recombinant AAV capsid comprising a mutation in aa 587-595 of the AAV8 capsid protein sequence as compared to the AAV8 wild type capsid sequence or a mutation in a corresponding region of another AAV capsid protein as compared to the corresponding wild type capsid sequence, further comprising a minigene comprising AAV inverted terminal repeats and a heterologous nucleic acid sequence operably linked to regulatory sequences which direct expression of a product encoded by the heterologous nucleic acid sequence in a target cell, and a pharmaceutically acceptable carrier, wherein the AAV capsid comprises the sequence of SEQ ID NO: 1 or SEQ ID NO: 2.

2. The method according to claim 1 , wherein the product encoded by the heterologous nucleic acid sequence is an opsin selected from rhodopsin, photopsin, L/M wavelength opsin (red/green)-opsin, short wavelength (S) opsin (blue), channelrhodopsin and halorhodopsin; NYX, GRM6, TRPM1L or GPR179.

3. The method according to claim 1 , wherein the composition is administered by subretinal injection.

4. The method according to claim 1 , wherein the subject has, or is at risk of developing, retinitis pigmentosa, rod-cone dystrophy, Leber's congenital amaurosis, Usher's syndrome, Bardet-Biedl Syndrome, Best disease, retinoschisis, Stargardt disease (autosomal dominant or autosomal recessive), untreated retinal detachment, pattern dystrophy, cone-rod dystrophy, achromatopsia, ocular albinism, enhanced S cone syndrome, diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity, sickle cell retinopathy, Congenital Stationary Night Blindness, retinal vein occlusion, glaucoma, Leber's hereditary optic neuropathy, lysosomal storage disorder, peroxisomal disorder.

5. The method according to claim 1 , wherein the effective concentration is about 10 9 to 10 13 genome copies per milliliter (GC/mL).

6. The method according to claim 1 , wherein the AAV is a self-complementary AAV.

7. A method of targeting bipolar cells for optogenetic therapy in a subject in need thereof, the method comprising administering to said subject an effective concentration of a composition comprising a recombinant adeno-associated virus (AAV) having a recombinant AAV capsid comprising a mutation in aa 587-595 of the AAV8 capsid protein sequence as compared to the AAV8 wild type capsid sequence or a mutation in a corresponding region of another AAV capsid protein as compared to the corresponding wild type capsid sequence, further comprising a minigene comprising AAV inverted terminal repeats and a heterologous nucleic acid sequence operably linked to regulatory sequences which direct expression of a product encoded by the heterologous nucleic acid sequence in a target cell, and a pharmaceutically acceptable carrier, wherein the AAV capsid comprises the sequence of SEQ ID NO: 1 or SEQ ID NO: 2.

8. A method of generating a recombinant adeno-associated virus (rAAV) comprising an AAV capsid comprising culturing a host cell containing: (a) a molecule encoding a recombinant AAV capsid protein characterized by a mutation in aa 587-595 as compared to the wild type AAV8 vp1 capsid sequence, or a mutation in the analogous region of another AAV capsid as compared to the corresponding AAV wild type capsid sequence, wherein the AAV capsid comprises the sequence of SEQ ID NO: 1 or SEQ ID NO: 2; (b) a functional rep gene; (c) a minigene comprising AAV inverted terminal repeats (ITRs) and a heterologous nucleic acid sequence operably linked to regulatory sequences which direct expression of a product encoded by the heterologous nucleic acid sequence in the target cell; and (d) sufficient helper functions to permit packaging of the minigene into the AAV capsid protein.

9. A method of delivering a transgene to a cell, said method comprising contacting the cell with an AAV having a recombinant AAV capsid comprising a mutation in aa 587-595 of the AAV8 capsid protein sequence as compared to the AAV8 wild type capsid sequence or a mutation in a corresponding region of another AAV capsid protein as compared to the corresponding wild type capsid sequence, further comprising a minigene comprising AAV inverted terminal repeats and a heterologous nucleic acid sequence operably linked to regulatory sequences which direct expression of a product encoded by the heterologous nucleic acid sequence in a target cell, wherein the AAV capsid comprises the sequence of SEQ ID NO: 1 or SEQ ID NO: 2 and a pharmaceutically acceptable carrier.

Assignees

• Univ Pennsylvania

Inventors

• Cronin Therese
• Bennett Jean
• Vandenberghe Luk E

Classifications

• A61K48/0058

  Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct · CPC title

• A61K38/177

  Receptors; Cell surface antigens; Cell surface determinants · CPC title

• C07K14/005

  from viruses · CPC title

• C12N2750/14121

  Viruses as such, e.g. new isolates, mutants or their genomic sequences · CPC title

• C12N2830/008

  cell type or tissue specific enhancer/promoter combination · CPC title